Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:GYRE NASDAQ:IMTX NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.60+1.3%$11.52$4.88▼$19.58$186.59MN/A87,039 shs139,793 shsGYREGyre Therapeutics$7.69+1.5%$7.60$6.11▼$19.00$740.65M1.8689,627 shs55,662 shsIMTXImmatics$6.26+9.4%$5.95$3.30▼$13.09$760.90M1.02823,409 shs3.22 million shsOCSOculis$17.22+0.3%$17.85$11.56▼$23.08$751.86M0.2611,177 shs16,386 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+3.61%-28.15%-27.18%+859,999,900.00%GYREGyre Therapeutics0.00%-0.65%+6.81%-8.56%-37.78%IMTXImmatics0.00%+22.99%-0.95%+4.86%-44.31%OCSOculis0.00%+6.76%-5.38%-13.55%+43.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.60+1.3%$11.52$4.88▼$19.58$186.59MN/A87,039 shs139,793 shsGYREGyre Therapeutics$7.69+1.5%$7.60$6.11▼$19.00$740.65M1.8689,627 shs55,662 shsIMTXImmatics$6.26+9.4%$5.95$3.30▼$13.09$760.90M1.02823,409 shs3.22 million shsOCSOculis$17.22+0.3%$17.85$11.56▼$23.08$751.86M0.2611,177 shs16,386 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+3.61%-28.15%-27.18%+859,999,900.00%GYREGyre Therapeutics0.00%-0.65%+6.81%-8.56%-37.78%IMTXImmatics0.00%+22.99%-0.95%+4.86%-44.31%OCSOculis0.00%+6.76%-5.38%-13.55%+43.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$32.60279.07% UpsideGYREGyre Therapeutics 3.00Buy$18.00134.07% UpsideIMTXImmatics 2.83Moderate Buy$14.67134.29% UpsideOCSOculis 3.00Buy$35.75107.61% UpsideCurrent Analyst Ratings BreakdownLatest AARD, IMTX, OCS, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $25.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/26/2025GYREGyre TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/14/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $19.006/30/2025AARDAardvark TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AGYREGyre Therapeutics$105.76M7.00$0.20 per share38.94$1.05 per share7.32IMTXImmatics$130.13M5.85$0.24 per share25.62$5.12 per share1.22OCSOculis$780K963.88N/AN/A$1.91 per share9.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/AGYREGyre Therapeutics$12.09M$0.01769.77∞N/A4.08%7.67%6.19%11/12/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)Latest AARD, IMTX, OCS, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/13/2025Q2 2025AARDAardvark Therapeutics-$0.52-$0.66-$0.14-$0.66N/AN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/11/2025Q2 2025GYREGyre Therapeutics$0.03$0.02-$0.01$0.04$30.80 million$26.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A14.0414.04GYREGyre TherapeuticsN/A5.404.87IMTXImmaticsN/A8.808.80OCSOculis0.014.554.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AGYREGyre Therapeutics23.99%IMTXImmatics64.41%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AGYREGyre Therapeutics10.00%IMTXImmatics3.30%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AGYREGyre Therapeutics4096.31 million86.68 millionNo DataIMTXImmatics260121.55 million117.54 millionOptionableOCSOculis243.66 millionN/ANot OptionableAARD, IMTX, OCS, and GYRE HeadlinesRecent News About These CompaniesOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?September 5 at 12:49 PM | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestSeptember 5 at 12:25 PM | marketbeat.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4 at 1:00 PM | globenewswire.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4 at 1:00 PM | globenewswire.comOculis Holding AG to Present Phase 2 ACUITY Trial Results for Privosegtor and Expanded Phase 3 DIAMOND Data at EURETINA CongressSeptember 1, 2025 | quiverquant.comQOculis Holding AG to Present Phase 2 and Phase 3 Clinical Trial Results at EURETINA and Other Key Ophthalmology ConferencesSeptember 1, 2025 | quiverquant.comQOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis (NASDAQ:OCS) Coverage Initiated at Needham & Company LLCAugust 29, 2025 | marketbeat.comOculis Holding AG Management to Participate in September Investor ConferencesAugust 28, 2025 | quiverquant.comQOculis Holding AG to Participate in Notable Investor Conferences in September 2025August 28, 2025 | quiverquant.comQOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comNeedham & Company LLC Initiates Coverage on Oculis (NASDAQ:OCS)August 28, 2025 | americanbankingnews.comOculis initiated with a Buy at NeedhamAugust 27, 2025 | msn.comOculis Holding AG $OCS Shares Bought by Pivotal bioVenture Partners Investment Advisor LLCAugust 26, 2025 | marketbeat.comOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology RespectivelyAugust 25, 2025 | quiverquant.comQOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and OphthalmologyAugust 25, 2025 | quiverquant.comQOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comOculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPSAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAARD, IMTX, OCS, and GYRE Company DescriptionsAardvark Therapeutics NASDAQ:AARD$8.60 +0.11 (+1.30%) As of 09/5/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Gyre Therapeutics NASDAQ:GYRE$7.69 +0.11 (+1.45%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.70 +0.00 (+0.07%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Immatics NASDAQ:IMTX$6.26 +0.54 (+9.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.16 -0.10 (-1.61%) As of 09/5/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Oculis NASDAQ:OCS$17.22 +0.06 (+0.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.26 +0.05 (+0.26%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
